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Reply to F. Felix et al and M.F. Fay et al
In our recent article in Journal of Clinical Oncology titled,
“Does Valproic Acid or Levetiracetam Improve Survival in
Glioblastoma? A Pooled Analysis of Prospective Clinical Trials
in Newly Diagnosed Glioblastoma,”1 we reported that drug
repurposing has attracted a lot of interest, speciﬁcally in
glioblastoma, given the disappointing results obtained with
initially promising, but ultimately inactive novel treatments
and the availability of large databases suitable for exploratory
analyses. In that regard, the potential impact on survival of the
anticonvulsant drug, valproic acid, has been in focus for more
than a decade. Yet, the pooled analysis of several contemporary
clinical trials that enrolled almost 2,000 patients, which set out
to strengthen the rationale for testing valproic acid in a ran-
domized deﬁnitive phase III trial in newly diagnosed glio-
blastoma, failed to provide an adequate signal to support such
a hypothesis in an otherwise molecularly unselected group of
adult glioblastoma.1
Felix and Fontenele2 rightly raise the issue that patients in
these trials were not enriched for any biomarker that predicted
potential beneﬁt from valproic acid and propose that valproic
acid be tested speciﬁcally in pediatric patients with H3F3A
mutation, mostly pontine gliomas. There is a possible biologic
and molecular rationale to explore valproic acid in this subgroup
of patients on the basis of the predicted epigenetic effects of
valproic acid; however, three issues arise. First, such patients are
relatively rare among those with glioblastoma and are un-
derrepresented in the patient cohorts studied in the trials
compiled for our analysis despite that our study included almost
2,000 patients (which underscores the rarity of this target).
Second, the concentrations of valproic acid required to inhibit
histone deacetylases may not be reached in human patients
in vivo.3 Third, is valproic acid truly the best histone deacetylase
inhibitor to study in this context?
Fay et al4 raise some methodological issues about our analysis.
They express concerns that confounders were not sufﬁciently
analyzed, but the analysis we presented was adjusted for known
important confounding factors, including O6-methylguanine DNA
methyltransferase promoter methylation status, and probably
represents one of the best efforts that could be done in the context
of clinical trial database analysis. The issue that sicker patients with
larger tumors were more likely to have received valproic acid due to
associated seizures was not substantiated by our database; there
were no particular clinical characteristics of valproic acid–treated
patients that differed from those not receiving it. That physicians
would be less inclined to give valproic acid to patients with larger
tumors with a higher bleeding propensity would argue against the
authors’ hypothesis that we overlooked an effect of valproic acid
because this would provide an even stronger bias in favor of su-
perior survival in the valproic acid groups. As discussed in the
present publication as well as in the initial report,5 the major
weakness we acknowledge is the lack of solid data on the dose and
duration of valproic acid exposure. Yet, the analysis was repeated at
clinically relevant time points (at baseline and after concomitant
temozolomide/radiotherapy) with the same conclusions. It is
conceivable that for a beneﬁcial effect in glioblastoma, early and
high-dose treatment with valproic acid would be required, al-
though no categorical data truly support this contention. Thus, we
contend that analyses such as those reported here are not suitable
to completely rule out an effect of valproic acid on outcome,
especially on minuscule subsets with unique biologic character-
istics. However, our data are robust enough to exclude any major
effect of valproic acid, especially in signiﬁcant proportions of pa-
tients with glioblastoma. Furthermore, any beneﬁcial effect would
have to be weighed against the major toxicity associated with
prolonged high-dose valproic acid treatment (eg, hematologic
abnormalities, hair loss, weight gain) in a patient population already
signiﬁcantly affected by other treatments such as corticosteroids,
irradiation, and alkylating agent chemotherapy.
We appreciate the interest of our colleagues in further
studying this topic, and we agree that further retrospective studies
are unlikely to resolve the issue unless we arrive at the conclusion
that we have deﬁnitively ruled out a major beneﬁt of valproic acid
in molecularly unselected newly diagnosed glioblastoma. In fact,
the European Organisation for Research and Treatment of Cancer
Brain Tumor Group has arrived at the latter conclusion and will
not further pursue the idea of a randomized phase III trial of
valproic acid in newly diagnosed glioblastoma.
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